In the PCa palliative group, the percentage of TNFRII-positive cells with strong immunoexpression was significantly higher (p < 0.001) vs. BPH and PCa surgery patients (Figure 4C). Here, TNFRSF1B is linked to benign prostatic hyperplasia.